VICE discusses the shortfalls of the soon-to-be enacted Psychoactive Substances Bill, including how it could push the drugs market further into obscurity.
Civil society organisations denounce the absence of harm reduction in the first draft of the UNGASS outcome document represents a step backwards from previously agreed language.
MAPS Founder speaks with psychedelic research advocates about psychedelic science, MDMA-assisted psychotherapy, and the prospect of making psychedelics legally available for medicinal purposes during a panel discussion at the 2015 International Drug Policy Reform Conference.
The government is examining the proposition to allow drug testing for purity at festivals and clubs as a move towards a harm reduction focused approach to the drug problem.
The event raised important points for discussion on the interactions between drug policy, harm reduction and development with a view to the upcoming UNGASS.
Following the success of the European Initiative Hepatitis C and Drug Use’s journal supplement “Viral Hepatitis and Drug Use in Europe", the Correlation Network is seeking original research articles on biomedical and public health aspects of HCV and drug use in Europe for publication.
The meeting organised by the Regional networks of Central, Eastern Europe, and Central Asia and their global counterparts focused on identifying priorities for the nearest future and sharing best practices.
80% of the world’s population is denied access to morphine – while 20% consume almost all of it. It is hard to think of a greater injustice that has largely arisen from the misunderstanding and fear of international drug policy. This is why IDHDP is launching its campaign: “Striving for equity in the treatment of pain”.
